BeOne Medicines (BEIGF) Gross Margin (2017 - 2026)

BeOne Medicines (BEIGF) has reported Gross Margin for 10 consecutive years, with 89.76% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin rose 228.0% year-over-year to 89.76% in Q2 2026; TTM through Jun 2026 was 88.89%, a 338.0% increase from a year earlier, with the FY2025 full-year figure at 87.49%, up 308.0% from the prior year.
• Gross Margin was 89.76% for Q2 2026 at BeOne Medicines, up from 88.95% in the prior quarter.
• Over five years, Gross Margin peaked at 90.49% in Q4 2025 and troughed at 78.72% in Q1 2022.
• A 5-year average of 84.48% and a median of 84.5% in 2024 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin tumbled 1588 bps in 2022 and surged 742 bps in 2023, its largest moves.
• Over 5 years, Gross Margin stood at 80.66% in 2022, then climbed by 3 bps to 83.32% in 2023, then rose by 3 bps to 85.76% in 2024, then climbed by 6 bps to 90.49% in 2025, then retreated by 1 bps to 89.76% in 2026.
• The last three Gross Margin figures came in at 89.76% (Q2 2026), 88.95% (Q1 2026), and 90.49% (Q4 2025), per Business Quant data.